Skip to main content
. 2019 Jun 2;2019:5952836. doi: 10.1155/2019/5952836

Figure 5.

Figure 5

Immune activities are positively associated with a 20-year survival prognosis in TP53-mutated BCs. (a) Kaplan-Meier survival curves show that the elevated enrichment of immune signatures is associated with a better 20-year survival in TP53-mutated BCs. (b) Kaplan-Meier survival curves show that higher expression levels of immune genes are associated with a better 20-year survival in TP53-mutated BCs. The log-rank test P<0.05 indicates the significance of survival-time differences between two classes of patients. HR: hazard ratio; CI: confidence interval.